IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit   : 1646
Examiner   :
Serial No.   : 09/825,378
Filed   : May 10, 2001
Inventors   : Michel Lazdunski
                 : Pierre Escoubas
                 : Jan DeWeille
                 : Sylvie Diochot
Title   : POLYPEPTIDE INHIBITING
                 : A PROTON-GATED Na+
                 : CHANNEL, A NUCLEIC ACID
                 : CODING FOR SUCH POLYPEPTIDE
                 : AND A METHOD OF MANUFACTURING
                 : AN ASIC1a CHANNEL BLOCKER

22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§1.821-1.825

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

RECEIVED

MAY 2 8 2003

TECH CENTER 1600/2900

Sir:

In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1.   The submission filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2.   The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and

3.   All statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements

910013_1

1

were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicant
Schnader Harrison Segal & Lewis LLP
1600 Market Street, Suite 3600
Philadelphia, PA 19103-7213

Date: October 14, 2002
TDC:gj
(215) 563-1810

910013_1

2

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: Brief description of drawings for figure 1 discloses sequences which is not identified by SEQ ID NO:.

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE